CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand
Olon Group is expanding its Italian site located in Settimo Torinese, a place that the active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) says is an asset of the global manufacturing network.
The company will be designing and operating the new area with advanced technologies that, relying on biomanufacturing knowledge, will produce proteins following highly sustainable processes, including microbial fermentation.
The expansion will allow Olon to increase its capacity to accommodate new and existing clients' needs, as it fits in the strategy of expanding the CDMO services in different market segments.
"We are significatively investing in our fermentation capacity following market trends that show an increased demand for microbial bio-manufactured compounds,” says Paolo Tubertini, Olon Group CEO. “Offering our expertise in CDMO services and biotechnological platforms as well, we are able to support innovative biotech companies to accelerate the development of new products, combining it with a more sustainable manufacturing approach."